OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 733
- 试验地点
- 1
- 主要终点
- Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1
研究概览
简要总结
OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent.
In this study we aim to explore at a primary care level whether the use of benchmarking against a set of guideline-based reference values on a patient basis, may improve quality of patient care, in particular control of diabetes, lipids and blood pressure.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects suffering from diabetes type 2,
- •treated or untreated,
- •insulin dependent or not insulin dependent Able to read and send SMS (if SMS applicable)
排除标准
- •Type 1 diabetes Pregnancy diabetes
- •Hospitalization at the moment of enrollment in the study
结局指标
主要结局
Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1
时间窗: after 12 months of follow-up
To investigate whether the use of benchmarking could improve quality of patient care, in particular the control of diabetes, lipids and blood pressure, expressed as the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1
次要结局
- The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines(after 12 months of follow-up versus baseline)
- Quality of patient care improvement, in particular the control of diabetes, lipids and blood pressure(after 12 months of follow-up versus baseline)
- Markers of preventive screening(after 12 months of follow-up versus baseline)